# The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer

> **NCT06086665** · — · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 850 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT06086665
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-01
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 850 (ACTUAL)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06086665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06086665, "The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06086665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*